Celesio AG sell hoffi69
Summary
This prediction ended on 14.03.11 with a price of €17.60. The SELL prediction by hoffi69 closed unchanged from the start price. hoffi69 has 50% into this predictionCelesio is a listed healthcare company that provides wholesale, delivery, and retail distribution services for pharmaceutical and healthcare products in Europe. The company operates through its three segments: Prescription Retail, Pharmacy Wholesale, and Consumer Solutions, and its services cater to individual customers, hospitals, and healthcare professionals. Celesio also offers digital healthcare solutions and operates pharmacies across Europe. As of July 2021, Celesio's stock is trading at approximately €25 per share on the Frankfurt Stock Exchange.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Celesio AG | - | - | - | - |
| iShares Core DAX® | -0.992% | -3.231% | 11.661% | 16.545% |
| iShares Nasdaq 100 | -0.225% | -3.339% | 36.491% | 43.334% |
| iShares Nikkei 225® | -0.736% | -7.859% | 18.597% | 4.253% |
| iShares S&P 500 | -0.509% | -2.979% | 26.341% | 40.911% |
Comments by hoffi69 for this prediction
In the thread Celesio AG diskutieren
Ertragsaussichten unattraktiv
Problematisch sind die Herausforderungen der Gesundheitsreform,die beim Pharmagroßhandel und im Apothekenbereich weitere Kosteneinsparungen fordern.Bezüglich Versandapotheken sinken die Margen weiter.die Preisspirale vieler rezeptpflichtiger Arzneimittel geht nach unten.Die statistische Erhöhung bei den Preisen wird nur durch wenige neue,patentgeschützte hochpreisige Arzneimittel verursacht.Insgesamt ist der Markt in Europa und besonders in Deutschland unattraktiv.Wenn Engagements im Pharmabereich,dann bei ausgewählten defensiven Titeln wie Novartis,Sanofi(über 5%Dividendenrendite)und evtl. Bayer.